# Evaluation of Tumor Control Based on Serial Multiparametric MRI and Post-Treatment Biopsies For Patients Treated With Dose Intensification to the Dominant Intra-Prostatic Lesion (DIL) Using Ultra-Hypofractionated, MR-Guided Radiotherapy

> **NCT06542757** · NA · RECRUITING · sponsor: **NYU Langone Health** · enrollment: 91 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **RADIATION:** 1.5 T Elekta Unity MR-Linac system
- **DEVICE:** Hydrogel rectal spacer (SpaceOAR)

## Key facts

- **NCT ID:** NCT06542757
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-09
- **Primary completion:** 2027-12
- **Final completion:** 2029-12
- **Target enrollment:** 91 (ESTIMATED)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06542757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06542757, "Evaluation of Tumor Control Based on Serial Multiparametric MRI and Post-Treatment Biopsies For Patients Treated With Dose Intensification to the Dominant Intra-Prostatic Lesion (DIL) Using Ultra-Hypofractionated, MR-Guided Radiotherapy". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06542757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*